Random Transgenic

rasH2 Random Transgenic Mouse Model

  • Model #
  • Genotype
  • Nomenclature
  • 1178-F
  • 1178-M
  • 1178-F
  • 1178-M
  • Carries the human homolog of the Harvey rat sarcoma virus oncogene (c-Ha-ras, now identified as HRAS) with its own promoter region in addition to the endogenous murine Ha-ras oncogene
  • Total ras-encoded p21 protein expressed at 2-3 times normal levels, in all tissues, with somatic mutational activation found only in tumor tissue transgenes
  • Significantly more rapid onset and higher incidence of more malignant tumors after treatment with genotoxic carcinogens compared to wild type controls
  • Very low incidence of spontaneous tumors, with no indication of pre-neoplastic cell stages or tumors at 6 months of age
  • Approximately 50% of transgenic rasH2 mice develop spontaneous tumors by 18 months of age, predominantly angiosarcomas and lung adenocarcinomas
  • Useful as a rapid, cost-effective, and sensitive carcinogenicity testing model for detection of nongenotoxic and genotoxic carcinogens, as supported by studies conducted by ILSI
  • Also useful in the study of oncogene-initiated tumorigenesis and can be used to evaluate tumor treatment compounds
  • In Japan, contact CIEA for purchase of rasH2 mice
  • Please note that the model nomenclature has been updated. The CIEA designation for the rasH2 model, CB6F1/Jic-TgrasH2@Tac was used previously.

Genetic Background:

BALB/cBy x C57BL/6 F1 Hybrid Background


The rasH2 mouse was developed in the laboratory of Tatsuji Nomura of the Central Institute for Experimental Animals (CIEA) in Kawaski, Japan. The model was created by microinjecting the human c-Ha-ras gene into C57BL/6 x BALB/c F2 zygotes. Hybrid transgenes were constructed from two human HRAS (c-Ha-ras) genes isolated from malignant melanoma and bladder carcinoma tumors. The transgene integrated into the murine transgenic genome as 5-6 copies in tandem array. The resultant mice were backcrossed to C57BL/6J. Taconic received stock in March 2000 and again in December 2005. The mice were derived by embryo transfer and are maintained by intercrossing C57BL/6JJic-Tg(HRAS)2Jic hemizygous male mice with BALB/cByJJic female mice.


Carries Nnt mutation


Black Agouti



Initial Publication:

Saitoh A, Kimura M, Takahasi R, Yokoyama M, Nomura T, Izawa M, Sckiya T, Nishimura S, Katsuki M. (1990) Most tumors in transgenic mice with human c-Ha-ras gene contained somatically activated transgenes. Oncogene, 5(8):1195-1200.

Conditions of Use for Taconic Transgenic Models™
Taconic Transgenic Models™ (Models) are produced and distributed under rights to patents and intellectual property licensed from various institutions. Taconic sells the Models to purchasers, grants to each purchaser a right under Taconic's rights in such licensed patents and intellectual property to use the purchased Model in consideration of purchasers' acknowledgement of and agreement to the Terms and Conditions of Sale and the following terms of use:
  • Title to these Models and biological materials derived from them remains with Taconic Biosciences, Inc.
  • The Models will be used for research purposes only.
  • The Models will not be bred except to obtain embryos or fetuses required for research purposes
  • The Models and biological materials derived from them will not be distributed to third parties or used for commercial purposes.